Human Genome Epidemiology Literature Finder
|
Records 1 - 22 (of 22 Records) |
| Query Trace: Breast Neoplasms and CYP2C8[original query] |
|---|
| Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. The pharmacogenomics journal 2007 Oct 7 (5): 362-5. Marsh S, Somlo G, Li X, Frankel P, King C R, Shannon W D, McLeod H L, Synold T |
| CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients. British journal of cancer 2009 Dec 101 (11): 1817-23. Jernström H, Bågeman E, Rose C, Jönsson P-E, Ingvar |
| Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients. Breast cancer research and treatment 2010 Nov 124 (2): 593-8. Rizzo Roberta, Spaggiari Federica, Indelli Monica, Lelli Giorgio, Baricordi Olavio R, Rimessi Paola, Ferlini Alessand |
| Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients. BMC medical genetics 2012 13 (1): 45. Seredina Tatyana A, Goreva Olga B, Talaban Valeria O, Grishanova Alevtina Yu, Lyakhovich Vyacheslav |
| CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast cancer research and treatment 2012 Jul 134 (1): 401-10. Hertz Daniel L, Motsinger-Reif Alison A, Drobish Amy, Winham Stacey J, McLeod Howard L, Carey Lisa A, Dees E Clai |
| New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw. Oral diseases 2012 Sep 18 (6): 580-5. Balla B, Vaszilko M, Kósa J P, Podani J, Takács I, Tóbiás B, Nagy Z, Lazáry A, Lakatos |
| Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status. Cancer causes & control : CCC 2013 May 24 (5): 929-40. Simonsson Maria, Söderlind Viktoria, Henningson Maria, Hjertberg Maria, Rose Carsten, Ingvar Christian, Jernström Hele |
| CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Jun 24 (6): 1472-8. Hertz D L, Roy S, Motsinger-Reif A A, Drobish A, Clark L S, McLeod H L, Carey L A, Dees E |
| Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer. Pharmacogenomics 2013 Oct 14 (13): 1583-92. Alcazar-González Gregorio Antonio, Calderón-Garcidueñas Ana Laura, Garza-Rodríguez María Lourdes, Rubio-Hernández Gabriela, Escorza-Treviño Sergio, Olano-Martin Estibaliz, Cerda-Flores Ricardo Martín, Castruita-Avila Ana Lilia, González-Guerrero Juan Francisco, le Brun Stéphane, Simon-Buela Laureano, Barrera-Saldaña Hugo Alber |
| Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach. Gene 2014 Jun 543 (1): 69-75. Tulsyan Sonam, Chaturvedi Pankaj, Singh Abhishek Kumar, Agarwal Gaurav, Lal Punita, Agrawal Sushma, Mittal Rama Devi, Mittal Balr |
| Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. Breast cancer research and treatment 2014 May 145 (1): 245-54. Hertz Daniel L, Roy Siddharth, Jack John, Motsinger-Reif Alison A, Drobish Amy, Clark L Scott, Carey Lisa A, Dees E Claire, McLeod Howard |
| Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy. Clinica chimica acta; international journal of clinical chemistry 2014 Jul 434 21-8. Tulsyan Sonam, Agarwal Gaurav, Lal Punita, Mittal Balr |
| SNPs and taxane toxicity in breast cancer patients. Pharmacogenomics 2014 15 (15): 1845-58. Bosó Virginia, Herrero María José, Santaballa Ana, Palomar Laura, Megias Juan E, de la Cueva Helena, Rojas Luis, Marqués María Remedios, Poveda José Luis, Montalar Joaquin, Aliño Salvador |
| Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. OncoTargets and therapy 2016 9 5073-80. Kus Tulay, Aktas Gokmen, Kalender Mehmet Emin, Demiryurek Abdullah Tuncay, Ulasli Mustafa, Oztuzcu Serdar, Sevinc Alper, Kul Seval, Camci Celaletd |
| Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients. British journal of cancer 2016 Oct . Lam Siu W, Frederiks Charlotte N, van der Straaten Tahar, Honkoop Aafke H, Guchelaar Henk-Jan, Boven Ep |
| Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment. Pharmacogenetics and genomics 2017 9 27 (11): 402-409. Marcath Lauren A, Deal Allison M, Van Wieren Emily, Danko William, Walko Christine M, Ibrahim Joseph G, Weck Karen E, Jones David R, Desta Zeruesenay, McLeod Howard L, Carey Lisa A, Irvin William J, Hertz Daniel |
| Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. Cancer chemotherapy and pharmacology 2017 Apr . Tanabe Yuko, Shimizu Chikako, Hamada Akinobu, Hashimoto Kenji, Ikeda Kazutaka, Nishizawa Daisuke, Hasegawa Junko, Shimomura Akihiko, Ozaki Yukinori, Tamura Nobuko, Yamamoto Harukaze, Yunokawa Mayu, Yonemori Kan, Takano Toshimi, Kawabata Hidetaka, Tamura Kenji, Fujiwara Yasuhi |
| Polymorphisms in Phase I (CYP450) Genes CYP1A1 (rs4646421), CYP1B1 (rs1056836), CYP19A1 (rs749292) and CYP2C8 (rs1058930) and Their Relation to Risk of Breast Cancer: A Case-Control Study in Mazandaran Province in North of Iran. Open access Macedonian journal of medical sciences 2019 Aug 7 (15): 2488-2496. Golmohammadzadeh Golpar, Mohammadpour Abbas, Ahangar Nematollah, Shokrzadeh Mohamm |
| Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). ESMO open 2020 Dec 6 (1): 100019. Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes A A, Foglietta J, Villa F, Todeschini R, Tognetto M, Naldi N, Bortesi B, Montemurro F, Ardizzoni A, Boni L, Musolino |
| Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis. Clinical and translational science 2022 Jul . Guijosa Alberto, Freyria Ana, Espinosa-Fernandez Jose Rodrigo, Estrada-Mena Francisco J, Armenta-Quiroga Ana Sofía, Ortega-Treviño Maria Fernanda, Catalán Rodrigo, Antonio-Aguirre Bani, Villarreal-Garza Cynthia, Perez-Ortiz Andric |
| Cytochrome P450 oxidoreductase, POR, associated with severe paclitaxel-induced peripheral neuropathy in patients of European ancestry from ECOG-ACRIN E5103. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 5 . Fei Shen, Guanglong Jiang, Santosh Philips, Laura Gardner, Gloria Xue, Erica Cantor, Reynold C Ly, Wilberforce Osei, Xi Wu, Chau Dang, Donald Northfelt, Todd Skaar, Kathy D Miller, George W Sledge, Bryan P Schneid |
| CYP2C8 rs11572080 and CYP3A4 rs2740574 risk genotypes in paclitaxel-treated premenopausal breast cancer patients. Scientific reports 2024 4 14 (1): 7922. Hanaa R M Attia, Mahmoud M Kamel, Dina F Ayoub, Shereen H Abd El-Aziz, Mai M Abdel Wahed, Safa N Abd El-Fattah, Mahmoud A Ablel-Monem, Thanaa M Rabah, Amany Helal, Mona Hamed Ibrah |
- Page last reviewed:Feb 1, 2024
- Content source: